



Egis Pharmaceuticals PLC

Keresztúri út 30-38.
H-1106 Budapest, Hungary

Phone: +36 1 803-5555

Fax: +36 1 803-5529
+36 1 803-5511

mailbox@egis.hu

www.egis.hu

Egis Pharmaceuticals PLC, headquartered in Budapest, Hungary, is one of the leading generics pharmaceutical companies operating principally in Central and Eastern Europe. The company's activities extend to every field of the pharmaceutical value chain: from R&D through the production of APIs and FPs to sales and marketing.

Egis' products are sold to 60 countries worldwide; besides Hungary the company sells its products under the brand name Egis in 17 countries through its network of subsidiaries and representative offices. Egis employs more than 4000 people in Hungary and abroad. In its 2014/2015 (Oct 2014 – Sept 2015) business year, Egis Group achieved net sales of EUR 418.6 million.

As an R&D-driven company, known for its high quality, value-added generic products, Egis devotes more than 10% of its consolidated turnover, more than EUR 42 million to research and development yearly. As a result of a 43 million EUR R&D investment program carried out in recent years, Egis has a wide range of generic drug R&D capacities at each of its three production sites, supporting the integrated development process of its generic drugs and APIs.

In the 2014/2015 business year the company's product portfolio consisted of 579 products. While the cardiovascular, central nervous systems account for the greatest share of the company's sales revenue, it continuously opens towards new therapeutic areas, including oncology.

In the framework of its agreement with Celltrion Group, in 2013 Egis launched its first biosimilar monoclonal antibody (mAB), which became the first biosimilar monoclonal antibody in the European Union approved by the European Medicines Agency (EMA).

Since 2013 Egis has launched the biosimilar monoclonal antibody in 13 countries of its strategically important regions.